Loading…

Sepsis biomarkers reprofiling to predict stroke-associated infections

We aimed to evaluate the usefulness of sepsis biomarkers to predict stroke-associated infections. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), mid-regional pro-adrenomedullin (MR-proADM), presepsin (sCD14), and soluble urokinase-type plasminogen activator receptor (suPAR), wer...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimmunology 2017-11, Vol.312, p.19-23
Main Authors: Bustamante, Alejandro, García-Berrocoso, Teresa, Penalba, Anna, Giralt, Dolors, Simats, Alba, Muchada, Marian, Zapata, Elena, Rubiera, Marta, Montaner, Joan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to evaluate the usefulness of sepsis biomarkers to predict stroke-associated infections. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), mid-regional pro-adrenomedullin (MR-proADM), presepsin (sCD14), and soluble urokinase-type plasminogen activator receptor (suPAR), were explored in 125 blood samples collected at different time-points. At baseline, MR-proADM was an independent predictor of infection [>0.94pg/mL, OR=3.63 (1.16–11.33), p=0.026], as well as suPAR at 24h [>2185.8pg/mL, OR=5.81 (1.05–32.26), p=0.044]. Both MR-proADM and suPAR were raised in patients with infections throughout the first week after stroke. These results are especially relevant for MR-proADM given its early elevation, which would allow early preventive interventions. [Display omitted] •Sepsis biomarkers could be useful in the management of stroke-associated infections.•We screened 4 sepsis biomarkers at three different time-points in stroke patients.•MR-proADM and sUPAR were independently associated with post-stroke infections.•MR-proADM is an early surrogate marker of stroke-associated infections.
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2017.08.012